Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
FZD4	rs10898563	AA	ranibizumab	efficacy	no	Response was measured by improvement in mean visual acuity, using either Snellen or Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity tests. Visual acuity was measured at baseline and after three monthly intravitreal ranibizumab injections.	Genotype AA is not associated with response to ranibizumab in people with Macular Degeneration as compared to genotype GG.	22840423	981755340
FZD4	rs10898563	AG	ranibizumab	efficacy	no	Response was measured by improvement in mean visual acuity, using either Snellen or Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity tests. Visual acuity was measured at baseline and after three monthly intravitreal ranibizumab injections.	Genotype AG is not associated with response to ranibizumab in people with Macular Degeneration as compared to genotype GG.	22840423	981755347
FZD4	rs10898563	G	bevacizumab	efficacy	no	Neovascular age-related macular degeneration. Response was based on the optical coherence tomography (OCT) metric of total retinal thickness (TRT). Change in TRT was calculated between baseline and after 3, 6, 9 or 12 months of treatment, depending on the patient. Eyes with TRT changes >= the 75th percentile were classified as responders; those with changes <= the 25th percentile were classified as nonresponders. Cases = responders; controls = nonresponders. p-value was Bonferroni-corrected for 3 tests.	Allele G is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to allele A.	24070809	1184165246